881 related articles for article (PubMed ID: 28848559)
1. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Gibbons Johnson RM; Dong H
Front Immunol; 2017; 8():961. PubMed ID: 28848559
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
3. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
5. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
7. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
9. Cell-intrinsic PD-L1 ablation sustains effector CD8
Wang X; Lu L; Hong X; Wu L; Yang C; Wang Y; Li W; Yang Y; Cao D; Di W; Deng L
Cell Rep; 2024 Feb; 43(2):113712. PubMed ID: 38294903
[TBL] [Abstract][Full Text] [Related]
10. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
11. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
[TBL] [Abstract][Full Text] [Related]
12. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
13. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
Barclay J; Creswell J; León J
Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
[TBL] [Abstract][Full Text] [Related]
15. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Karim R; Jordanova ES; Piersma SJ; Kenter GG; Chen L; Boer JM; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Oct; 15(20):6341-7. PubMed ID: 19825956
[TBL] [Abstract][Full Text] [Related]
16. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
18. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.
Schreiner B; Bailey SL; Shin T; Chen L; Miller SD
Eur J Immunol; 2008 Oct; 38(10):2706-17. PubMed ID: 18825752
[TBL] [Abstract][Full Text] [Related]
19. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma.
Han L; Liu F; Li R; Li Z; Chen X; Zhou Z; Zhang X; Hu T; Zhang Y; Young K; Sun S; Wen J; Zhang M
Oncol Lett; 2014 Oct; 8(4):1461-1469. PubMed ID: 25202350
[TBL] [Abstract][Full Text] [Related]
20. Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade.
Mitsuhashi A; Koyama K; Ogino H; Afroj T; Nguyen NT; Yoneda H; Otsuka K; Sugimoto M; Kondoh O; Nokihara H; Hanibuchi M; Takizawa H; Shinohara T; Nishioka Y
Cell Rep; 2023 Mar; 42(3):112162. PubMed ID: 36870329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
